Breaking Finance News

Mizuho Securities disclosed Celgene Corporation (NDAQ:CELG), stepping up its target to $158.00 earlier today

In a report issued 9/15/2017 Mizuho Securities raised the target price of Celgene Corporation (NDAQ:CELG) from $134.00 to $158.00 reporting a possible upside of 0.11%.

On Friday July 28, 2017, Stifel Nicolaus released a statement on Celgene Corporation (NDAQ:CELG) raised the target price from $0.00 to $155.00 that suggested an upside of 0.16%.

Having a price of $142.18, Celgene Corporation (NDAQ:CELG) traded -0.50% lower on the day. The last stock price is up 10.40% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. The company has recorded a 50-day moving average of $134.74 and a 200-day moving average of $127.31. 3,074,739 shares of Celgene Corporation exchanged hands, down from an average trading volume of 3,813,030

See Chart Below

Celgene Corporation (NDAQ:CELG)

With a total market value of $0, Celgene Corporation has price-earnings ratio of 43.53 with a 52 week low of $96.93 and a 52 week high of $142.64 .

In addition to Mizuho Securities reporting its stock price target, a total of 22 analysts have released a report on Celgene Corporation. The 12-month price target is $136.82 with 10 brokerages rating the stock a strong buy, 10 equity analysts rating the company a buy, four equity analysts rating the company a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Celgene Corporation (NDAQ:CELG)

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.